[144] Ascendis Pharma A/S American SEC Filing
Ascendis Pharma A/S (ASND) filed a Form 144 notifying the proposed sale of 9,375 American Depositary Shares on 08/15/2025 through Merrill Lynch on NASDAQ. The filing reports an aggregate market value of $1,826,403.05 and total shares outstanding of 60,454,589. The shares were acquired the same day by warrant exercise from Ascendis Pharma A/S, with cash payment. The filer reports no securities sold in the past three months. The notice includes the standard signature representation that the seller is not aware of any undisclosed material adverse information.
Ascendis Pharma A/S (ASND) ha depositato un Modulo 144 notificando la proposta vendita di 9.375 American Depositary Shares il 15/08/2025 tramite Merrill Lynch sul NASDAQ. Il deposito indica un valore di mercato complessivo di $1.826.403,05 e un totale di azioni in circolazione pari a 60.454.589. Le azioni sono state acquisite lo stesso giorno mediante esercizio di warrant da Ascendis Pharma A/S, con pagamento in contanti. Il dichiarante segnala che non sono stati venduti titoli nei precedenti tre mesi. L鈥檃vviso include la dichiarazione standard in cui il venditore attesta di non essere a conoscenza di informazioni materiali non divulgate.
Ascendis Pharma A/S (ASND) present贸 un Formulario 144 notificando la propuesta de venta de 9.375 American Depositary Shares el 15/08/2025 a trav茅s de Merrill Lynch en NASDAQ. La presentaci贸n reporta un valor de mercado agregado de $1.826.403,05 y un total de acciones en circulaci贸n de 60.454.589. Las acciones fueron adquiridas el mismo d铆a mediante ejercicio de warrants de Ascendis Pharma A/S, con pago en efectivo. El declarante informa que no ha vendido valores en los 煤ltimos tres meses. El aviso incluye la representaci贸n est谩ndar de firma en la que el vendedor declara no tener conocimiento de informaci贸n material no divulgada.
Ascendis Pharma A/S (ASND)电� Form 144毳� 鞝滌稖頃橃棳 2025-08-15鞐� Merrill Lynch毳� 韱淀暣 NASDAQ鞐愳劀 9,375 American Depositary Shares鞚� 毵る弰毳� 鞝滌晥頄堨潓鞚� 韱奠頄堨姷雼堧嫟. 鞝滌稖靹滌棎 霐半ゴ氅� 齑� 鞁滉皜鞎§潃 $1,826,403.05鞚搓碃 齑� 氚滍枆 欤检嫕 靾樀鐢 60,454,589欤�鞛呺媹雼�. 頃措嫻 欤检嫕鞚� 臧欖潃 雮� Ascendis Pharma A/S鞚� 鞗岆煱韸� 頄夓偓搿� 旆摑霅橃棃鞙茧┌, 顺勱笀鞙茧 瓴办牅霅橃棃鞀惦媹雼�. 鞝滌稖鞛惖鐢 歆�雮� 3臧滌洈 霃欖晥 韺愲Г頃� 歃濌秾鞚� 鞐嗠嫟瓿� 氤搓碃頄堨姷雼堧嫟. 韱奠靹滌棎电� 韺愲Г鞛愱皜 瓿店皽霅橃 鞎婌潃 欷戨寑頃� 攵堧Μ頃� 鞝曤炒臧� 鞐嗢潓鞚� 頇曥澑頃樀鐢 響滌 靹滊獏 歆勳垹鞚� 韽暔霅橃柎 鞛堨姷雼堧嫟.
Ascendis Pharma A/S (ASND) a d茅pos茅 un Formulaire 144 notifiant la proposition de vente de 9 375 American Depositary Shares le 15/08/2025 via Merrill Lynch sur le NASDAQ. Le d茅p么t indique une valeur de march茅 agr茅g茅e de 1 826 403,05 $ et un total d'actions en circulation de 60 454 589. Les actions ont 茅t茅 acquises le m锚me jour par exercice de warrant d'Ascendis Pharma A/S, avec paiement en 别蝉辫猫肠别蝉. Le d茅clarant pr茅cise qu'aucun titre n'a 茅t茅 vendu au cours des trois derniers mois. L'avis comprend la d茅claration standard selon laquelle le vendeur n'a connaissance d'aucune information d茅favorable importante non divulgu茅e.
Ascendis Pharma A/S (ASND) reichte ein Formular 144 ein und meldete den geplanten Verkauf von 9.375 American Depositary Shares am 15.08.2025 眉ber Merrill Lynch an der NASDAQ. Die Einreichung weist einen gesamten Marktwert von $1.826.403,05 und insgesamt 60.454.589 ausstehende Aktien aus. Die Aktien wurden am selben Tag durch 奥补谤谤补苍迟-础耻蝉眉产耻苍驳 von Ascendis Pharma A/S erworben und bar bezahlt. Der Einreicher berichtet, in den letzten drei Monaten keine Wertpapiere verkauft zu haben. Die Mitteilung enth盲lt die 眉bliche Unterschriftsbest盲tigung, dass dem Verk盲ufer keine nicht offengelegten, wesentlichen nachteiligen Informationen bekannt sind.
- None.
- None.
Insights
TL;DR Routine notification of a small block sale of ADSs acquired by warrant exercise; no recent selling activity reported.
The Form 144 documents a proposed sale of 9,375 ADSs with an aggregate value of $1.83 million, to be executed on 08/15/2025 via Merrill Lynch on NASDAQ. The securities were acquired the same day by warrant exercise and paid for in cash. The filer indicates no sales in the prior three months, suggesting this filing represents an isolated disposition rather than sustained selling. The disclosure is procedural and provides limited new information about company operations or financial condition.
TL;DR Administrative compliance filing that fulfills Rule 144 notice requirements; includes standard attestation about undisclosed material information.
The submission meets Rule 144 notice requirements by identifying the class of securities, broker, number of ADSs, aggregate market value, share count outstanding, acquisition method and payment. The filing contains the customary attestation regarding the absence of undisclosed material adverse information and notes no sales in the prior three months. There are no governance changes, insider departures, or other corporate actions disclosed in this notice.
Ascendis Pharma A/S (ASND) ha depositato un Modulo 144 notificando la proposta vendita di 9.375 American Depositary Shares il 15/08/2025 tramite Merrill Lynch sul NASDAQ. Il deposito indica un valore di mercato complessivo di $1.826.403,05 e un totale di azioni in circolazione pari a 60.454.589. Le azioni sono state acquisite lo stesso giorno mediante esercizio di warrant da Ascendis Pharma A/S, con pagamento in contanti. Il dichiarante segnala che non sono stati venduti titoli nei precedenti tre mesi. L鈥檃vviso include la dichiarazione standard in cui il venditore attesta di non essere a conoscenza di informazioni materiali non divulgate.
Ascendis Pharma A/S (ASND) present贸 un Formulario 144 notificando la propuesta de venta de 9.375 American Depositary Shares el 15/08/2025 a trav茅s de Merrill Lynch en NASDAQ. La presentaci贸n reporta un valor de mercado agregado de $1.826.403,05 y un total de acciones en circulaci贸n de 60.454.589. Las acciones fueron adquiridas el mismo d铆a mediante ejercicio de warrants de Ascendis Pharma A/S, con pago en efectivo. El declarante informa que no ha vendido valores en los 煤ltimos tres meses. El aviso incluye la representaci贸n est谩ndar de firma en la que el vendedor declara no tener conocimiento de informaci贸n material no divulgada.
Ascendis Pharma A/S (ASND)电� Form 144毳� 鞝滌稖頃橃棳 2025-08-15鞐� Merrill Lynch毳� 韱淀暣 NASDAQ鞐愳劀 9,375 American Depositary Shares鞚� 毵る弰毳� 鞝滌晥頄堨潓鞚� 韱奠頄堨姷雼堧嫟. 鞝滌稖靹滌棎 霐半ゴ氅� 齑� 鞁滉皜鞎§潃 $1,826,403.05鞚搓碃 齑� 氚滍枆 欤检嫕 靾樀鐢 60,454,589欤�鞛呺媹雼�. 頃措嫻 欤检嫕鞚� 臧欖潃 雮� Ascendis Pharma A/S鞚� 鞗岆煱韸� 頄夓偓搿� 旆摑霅橃棃鞙茧┌, 顺勱笀鞙茧 瓴办牅霅橃棃鞀惦媹雼�. 鞝滌稖鞛惖鐢 歆�雮� 3臧滌洈 霃欖晥 韺愲Г頃� 歃濌秾鞚� 鞐嗠嫟瓿� 氤搓碃頄堨姷雼堧嫟. 韱奠靹滌棎电� 韺愲Г鞛愱皜 瓿店皽霅橃 鞎婌潃 欷戨寑頃� 攵堧Μ頃� 鞝曤炒臧� 鞐嗢潓鞚� 頇曥澑頃樀鐢 響滌 靹滊獏 歆勳垹鞚� 韽暔霅橃柎 鞛堨姷雼堧嫟.
Ascendis Pharma A/S (ASND) a d茅pos茅 un Formulaire 144 notifiant la proposition de vente de 9 375 American Depositary Shares le 15/08/2025 via Merrill Lynch sur le NASDAQ. Le d茅p么t indique une valeur de march茅 agr茅g茅e de 1 826 403,05 $ et un total d'actions en circulation de 60 454 589. Les actions ont 茅t茅 acquises le m锚me jour par exercice de warrant d'Ascendis Pharma A/S, avec paiement en 别蝉辫猫肠别蝉. Le d茅clarant pr茅cise qu'aucun titre n'a 茅t茅 vendu au cours des trois derniers mois. L'avis comprend la d茅claration standard selon laquelle le vendeur n'a connaissance d'aucune information d茅favorable importante non divulgu茅e.
Ascendis Pharma A/S (ASND) reichte ein Formular 144 ein und meldete den geplanten Verkauf von 9.375 American Depositary Shares am 15.08.2025 眉ber Merrill Lynch an der NASDAQ. Die Einreichung weist einen gesamten Marktwert von $1.826.403,05 und insgesamt 60.454.589 ausstehende Aktien aus. Die Aktien wurden am selben Tag durch 奥补谤谤补苍迟-础耻蝉眉产耻苍驳 von Ascendis Pharma A/S erworben und bar bezahlt. Der Einreicher berichtet, in den letzten drei Monaten keine Wertpapiere verkauft zu haben. Die Mitteilung enth盲lt die 眉bliche Unterschriftsbest盲tigung, dass dem Verk盲ufer keine nicht offengelegten, wesentlichen nachteiligen Informationen bekannt sind.
